• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

通过米氏-阿尔布佐夫反应或普多夫尼克反应获得的双膦酸衍生物的细胞毒性活性。

Cytotoxic Activity of Bisphosphonic Derivatives Obtained by the Michaelis-Arbuzov or the Pudovik Reaction.

作者信息

Szalai Zsuzsanna, Bednárik Janka, Tóth Boldizsár Szigfrid, Takács Angéla, Tekula Szilárd, Kőhidai László, Karaghiosoff Konstantin, Drahos László, Keglevich György

机构信息

Department of Organic Chemistry and Technology, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, Műegyetem rkp. 3, 1111 Budapest, Hungary.

Department of Genetics, Cell and Immunobiology, Semmelweis University, Nagyvárad tér 4, 1089 Budapest, Hungary.

出版信息

Pharmaceuticals (Basel). 2025 Jan 13;18(1):91. doi: 10.3390/ph18010091.

DOI:10.3390/ph18010091
PMID:39861154
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11768586/
Abstract

Methylenebisphosphonic derivatives including hydroxy-methylenebisphosphonic species may be of potential biological activity, and a part of them is used in the treatment of bone diseases. Methylenebisphosphonates may be obtained by the Michaelis-Arbuzov reaction of suitably α-substituted methylphosphonates and trialkyl phosphites or phosphinous esters, while the hydroxy-methylene variations are prepared by the Pudovik reaction of α-oxophosphonates and different >P(O)H reagents, such as diethyl phosphite and diarylphosphine oxides. After converting α-hydroxy-benzylphosphonates and -phosphine oxides to the α-halogeno- and α-sulfonyloxy derivatives, they were utilized in the Michaelis-Arbuzov reaction with trialkyl phosphites and ethyl diphenylphosphinite to afford the corresponding bisphosphonate, bis(phosphine oxide) and phosphonate-phosphine oxide derivatives. The Pudovik approach led to α-hydroxy-methylenebisphosphonic species and to their rearranged products. A part of the derivatives revealed a significant cytotoxic effect on pancreatic adenocarcinoma or multiple myeloma cells. The new families of compounds synthesized by our novel approaches may be of practical importance due to the significant cytotoxic activity on the cell cultures investigated. Compounds lacking hydroxy groups showed anti-myeloma activity or limited effect on pancreatic cancer (PANC-1) cells unless substituted with para-trifluoromethyl group. Hydroxy-containing bisphosphonates and their rearranged derivatives demonstrated varying effects depending on structural modifications. While myeloma (U266) cells indicated greater sensitivity overall, the most significant reductions in cell viability were observed in PANC-1 cancer cells, raising potential therapeutic applications of bisphosphonates beyond myeloma-associated bone disease, particularly for malignancies like pancreatic ductal adenocarcinoma.

摘要

包括羟基亚甲基双膦酸类物质在内的亚甲基双膦酸衍生物可能具有潜在的生物活性,其中一部分用于治疗骨疾病。亚甲基双膦酸酯可通过适当的α-取代甲基膦酸酯与亚磷酸三烷基酯或亚膦酸酯的米氏-阿尔布佐夫反应制得,而羟基亚甲基变体则通过α-氧代膦酸酯与不同的>P(O)H试剂(如亚磷酸二乙酯和二芳基氧化膦)的普多维克反应制备。将α-羟基苄基膦酸酯和氧化膦转化为α-卤代和α-磺酰氧基衍生物后,它们被用于与亚磷酸三烷基酯和乙基二苯基次膦酸酯的米氏-阿尔布佐夫反应,以得到相应的双膦酸酯、双(氧化膦)和膦酸酯-氧化膦衍生物。普多维克方法得到了α-羟基亚甲基双膦酸类物质及其重排产物。一部分衍生物对胰腺腺癌或多发性骨髓瘤细胞显示出显著的细胞毒性作用。通过我们的新方法合成的新化合物家族由于对所研究的细胞培养物具有显著的细胞毒性活性而可能具有实际重要性。缺乏羟基的化合物显示出抗骨髓瘤活性或对胰腺癌细胞(PANC-1)的作用有限,除非被对三氟甲基取代。含羟基的双膦酸酯及其重排衍生物根据结构修饰表现出不同的效果。虽然骨髓瘤(U266)细胞总体上显示出更高的敏感性,但在PANC-癌细胞中观察到细胞活力的最显著降低,这提高了双膦酸酯在骨髓瘤相关骨疾病之外的潜在治疗应用,特别是对于胰腺导管腺癌等恶性肿瘤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/700417957367/pharmaceuticals-18-00091-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/077186a4515f/pharmaceuticals-18-00091-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/0c5fc6672c39/pharmaceuticals-18-00091-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/922dbc8075fb/pharmaceuticals-18-00091-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/0bcf9ebd5b2a/pharmaceuticals-18-00091-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/683562924d3c/pharmaceuticals-18-00091-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/403ce9924737/pharmaceuticals-18-00091-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/343464c13b64/pharmaceuticals-18-00091-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/437d686f8a2f/pharmaceuticals-18-00091-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/76045dd1b0ad/pharmaceuticals-18-00091-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/46afbdd8345d/pharmaceuticals-18-00091-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/7b8765c07764/pharmaceuticals-18-00091-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/a95503e9736c/pharmaceuticals-18-00091-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/aee3b23bded7/pharmaceuticals-18-00091-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/970cc234fa93/pharmaceuticals-18-00091-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/4e61d1daa4e4/pharmaceuticals-18-00091-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/085c2421f2d1/pharmaceuticals-18-00091-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/17d3b38d005e/pharmaceuticals-18-00091-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/b2632cc03433/pharmaceuticals-18-00091-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/700417957367/pharmaceuticals-18-00091-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/077186a4515f/pharmaceuticals-18-00091-sch001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/0c5fc6672c39/pharmaceuticals-18-00091-sch002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/922dbc8075fb/pharmaceuticals-18-00091-sch003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/0bcf9ebd5b2a/pharmaceuticals-18-00091-sch004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/683562924d3c/pharmaceuticals-18-00091-sch005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/403ce9924737/pharmaceuticals-18-00091-sch006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/343464c13b64/pharmaceuticals-18-00091-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/437d686f8a2f/pharmaceuticals-18-00091-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/76045dd1b0ad/pharmaceuticals-18-00091-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/46afbdd8345d/pharmaceuticals-18-00091-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/7b8765c07764/pharmaceuticals-18-00091-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/a95503e9736c/pharmaceuticals-18-00091-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/aee3b23bded7/pharmaceuticals-18-00091-sch007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/970cc234fa93/pharmaceuticals-18-00091-sch008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/4e61d1daa4e4/pharmaceuticals-18-00091-sch009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/085c2421f2d1/pharmaceuticals-18-00091-sch010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/17d3b38d005e/pharmaceuticals-18-00091-sch011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/b2632cc03433/pharmaceuticals-18-00091-sch012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9027/11768586/700417957367/pharmaceuticals-18-00091-g007.jpg

相似文献

1
Cytotoxic Activity of Bisphosphonic Derivatives Obtained by the Michaelis-Arbuzov or the Pudovik Reaction.通过米氏-阿尔布佐夫反应或普多夫尼克反应获得的双膦酸衍生物的细胞毒性活性。
Pharmaceuticals (Basel). 2025 Jan 13;18(1):91. doi: 10.3390/ph18010091.
2
A Study of the Bisphosphonic Derivatives from the Pudovik Reaction of Dialkyl α-Oxophosphonates and >P(O)H Reagents: X-ray Structure and Bioactivity.从二烷基 α-氧膦酸酯和>P(O)H 试剂的 Pudovik 反应中得到的双膦酸衍生物的研究:X 射线结构和生物活性。
Molecules. 2023 Aug 12;28(16):6037. doi: 10.3390/molecules28166037.
3
The Synthesis, Crystal Structure, Modification, and Cytotoxic Activity of α-Hydroxy-Alkylphosphonates.α-羟基-烷基膦酸酯的合成、晶体结构、修饰及细胞毒性活性
Molecules. 2025 Jan 20;30(2):428. doi: 10.3390/molecules30020428.
4
Unexpected Reaction of Dialkyl α-Hydroxy-benzylphosphonates with Dialkyl Phosphites and a Few Related Reactions.二烷基α-羟基苄基膦酸酯与亚磷酸二烷基酯的意外反应及一些相关反应
J Org Chem. 2025 Jan 10;90(1):439-447. doi: 10.1021/acs.joc.4c02355. Epub 2024 Dec 17.
5
Tetraalkyl Hydroxymethylene-bisphosphonate and Dialkyl 1-Diphenylphosphinoyl-1-hydroxy-ethylphosphonate Derivatives by the Pudovik Reaction and Their Rearranged Products.四烷基亚甲基双膦酸酯和二烷基亚膦酰基-1-二苯氧膦基-1-羟乙基膦酸酯衍生物的普多夫金反应及其重排产物。
Molecules. 2021 Dec 14;26(24):7575. doi: 10.3390/molecules26247575.
6
Synthesis of Mesylated and Tosylated α-Hydroxy-Benzylphosphonates; Their Reactivity and Cytostatic Activity.甲磺酰化和对甲苯磺酰化α-羟基苄基膦酸酯的合成;它们的反应活性和细胞生长抑制活性。
ACS Omega. 2024 Jul 2;9(28):31043-31055. doi: 10.1021/acsomega.4c04382. eCollection 2024 Jul 16.
7
Improvements, Variations and Biomedical Applications of the Michaelis-Arbuzov Reaction.迈克尔利斯-阿尔布佐夫反应的改进、变化及生物医学应用。
Int J Mol Sci. 2022 Mar 21;23(6):3395. doi: 10.3390/ijms23063395.
8
Synthesis of α-Aminophosphonates and Related Derivatives; the Last Decade of the Kabachnik-Fields Reaction.α-氨基膦酸酯及其相关衍生物的合成;Kabachnik-Fields 反应的最后十年。
Molecules. 2021 Apr 25;26(9):2511. doi: 10.3390/molecules26092511.
9
Enantioseparation of -Stereogenic Secondary Phosphine Oxides and Their Stereospecific Transformation to Various Tertiary Phosphine Oxides and a Thiophosphinate.- 手性仲膦氧化物的对映体拆分及其向各种叔膦氧化物和硫代次膦酸酯的立体专一性转化
J Org Chem. 2021 Nov 5;86(21):14493-14507. doi: 10.1021/acs.joc.1c01364. Epub 2021 Oct 11.
10
The typical crystal structures of a few representative α-aryl-α-hydroxyphosphonates.几种代表性α-芳基-α-羟基膦酸酯的典型晶体结构。
Acta Crystallogr C Struct Chem. 2019 Mar 1;75(Pt 3):283-293. doi: 10.1107/S2053229619001839. Epub 2019 Feb 12.

引用本文的文献

1
Synthesis and Cytotoxic Activity of a New Family of α-Hydroxyphosphonates with the Benzothiophene Scaffold.含苯并噻吩骨架的新型α-羟基膦酸酯类化合物的合成及其细胞毒性活性
Pharmaceuticals (Basel). 2025 Jun 24;18(7):949. doi: 10.3390/ph18070949.

本文引用的文献

1
Synthesis of Mesylated and Tosylated α-Hydroxy-Benzylphosphonates; Their Reactivity and Cytostatic Activity.甲磺酰化和对甲苯磺酰化α-羟基苄基膦酸酯的合成;它们的反应活性和细胞生长抑制活性。
ACS Omega. 2024 Jul 2;9(28):31043-31055. doi: 10.1021/acsomega.4c04382. eCollection 2024 Jul 16.
2
A Study of the Bisphosphonic Derivatives from the Pudovik Reaction of Dialkyl α-Oxophosphonates and >P(O)H Reagents: X-ray Structure and Bioactivity.从二烷基 α-氧膦酸酯和>P(O)H 试剂的 Pudovik 反应中得到的双膦酸衍生物的研究:X 射线结构和生物活性。
Molecules. 2023 Aug 12;28(16):6037. doi: 10.3390/molecules28166037.
3
Visible-Light-Induced Carbene Insertion into P-H Bonds between Acylsilanes and -Phosphorus Oxides.
可见光照耀下酰基硅烷与膦氧化物中 P-H 键的卡宾插入反应。
Org Lett. 2023 Apr 7;25(13):2338-2343. doi: 10.1021/acs.orglett.3c00722. Epub 2023 Mar 28.
4
Investigation of the Antitumor Effects of Tamoxifen and Its Ferrocene-Linked Derivatives on Pancreatic and Breast Cancer Cell Lines.他莫昔芬及其二茂铁连接衍生物对胰腺和乳腺癌细胞系的抗肿瘤作用研究。
Pharmaceuticals (Basel). 2022 Mar 5;15(3):314. doi: 10.3390/ph15030314.
5
The Synergistic Activity of Bortezomib and TIC10 against A2058 Melanoma Cells.硼替佐米与TIC10对A2058黑色素瘤细胞的协同活性
Pharmaceuticals (Basel). 2021 Aug 20;14(8):820. doi: 10.3390/ph14080820.
6
What Do We Know About Clodronate Now? A Medical and Veterinary Perspective.目前我们对氯膦酸二钠了解多少?从医学和兽医角度来看。
J Equine Vet Sci. 2020 May;88:102874. doi: 10.1016/j.jevs.2019.102874. Epub 2019 Nov 23.
7
Antiproliferative and antimigratory activities of bisphosphonates in human breast cancer cell line MCF-7.双膦酸盐在人乳腺癌细胞系MCF-7中的抗增殖和抗迁移活性。
Oncol Lett. 2019 Aug;18(2):1246-1258. doi: 10.3892/ol.2019.10438. Epub 2019 Jun 5.
8
Bisphosphonates in multiple myeloma: an updated network meta-analysis.双膦酸盐类药物在多发性骨髓瘤中的应用:一项更新的网状Meta分析
Cochrane Database Syst Rev. 2017 Dec 18;12(12):CD003188. doi: 10.1002/14651858.CD003188.pub4.
9
Synthesis of Hydroxymethylenebisphosphonic Acid Derivatives in Different Solvents.不同溶剂中羟基亚甲基双膦酸衍生物的合成
Molecules. 2016 Aug 11;21(8):1046. doi: 10.3390/molecules21081046.
10
Potentiating the Anticancer Properties of Bisphosphonates by Nanocomplexation with the Cationic Amphipathic Peptide, RALA.通过与阳离子两亲性肽RALA形成纳米复合物增强双膦酸盐的抗癌特性
Mol Pharm. 2016 Apr 4;13(4):1217-28. doi: 10.1021/acs.molpharmaceut.5b00670. Epub 2016 Mar 22.